Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins.

ABSTRACT: More than one and half years have passed, as of August 2021, since the COVID-19 caused by the novel coronavirus named SARS-CoV-2 emerged in 2019. While the recent success of vaccine developments likely reduces the severe cases, there is still a strong requirement of safety and effective therapeutic drugs for overcoming the unprecedented situation. Here we review the recent progress and the status of the drug discovery against COVID-19 with emphasizing a structure-based perspective. Structural data regarding the SARS-CoV-2 proteome has been rapidly accumulated in the Protein Data Bank, and up to 68% of the total amino acid residues encoded in the genome were covered by the structural data. Despite a global effort of in silico and in vitro screenings for drug repurposing, there

SUBMITTER: Hijikata A 

PROVIDER: S-EPMC8550875 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature